Gröhn P, Kumpulainen E, Nuortio L, Hakala T, Vuoristo M S, Korpela M, Heikkinen M, Salmi R, Jakobsson M, Numminen S
Eerontie 1 B, Espoo, Finland.
Eur J Cancer. 1992;28(2-3):441-3. doi: 10.1016/s0959-8049(05)80072-3.
52 patients with metastatic melanoma have been treated with a combination of recombinant interferon-alfa-2b, dacarbazine and nimustine. The objective response rate was 23% with 9 complete responses (CR) and 3 partial responses (PR). The mean duration of the response was 18+ months for CR (6-31+ months) and 7 months for PR patients (4-10 months). The mean survivals were 24+ months (8-38 months) and 7 months (4-12 months), respectively. The mean duration of the response for patients with stable disease was 10+ months (2-48+ months) and the mean survival 17+ months (3-48+ months), while the patients with progressive disease died within 12 months (mean 4 months). The best responding sites were the lymph node, the lung and the subcutaneous metastases. Myelosuppression was the main adverse effect of the therapy. WHO grade 3-4 toxicity was seen in 27 patients leading to delay and reduced dosage of therapy; in 4 patients treatment was discontinued, 8 patients had no side effects. Combination therapy with interferon and dacarbazine and nimustine for metastatic melanoma offers no advantage over interferon and dacarbazine.
52例转移性黑色素瘤患者接受了重组干扰素α-2b、达卡巴嗪和尼莫司汀联合治疗。客观缓解率为23%，其中9例完全缓解（CR），3例部分缓解（PR）。CR患者的平均缓解持续时间为18 +个月（6 - 31 +个月），PR患者为7个月（4 - 10个月）。平均生存期分别为24 +个月（8 - 38个月）和7个月（4 - 12个月）。疾病稳定患者的平均缓解持续时间为10 +个月（2 - 48 +个月），平均生存期为17 +个月（3 - 48 +个月），而疾病进展患者在12个月内死亡（平均4个月）。最佳缓解部位为淋巴结、肺和皮下转移灶。骨髓抑制是该治疗的主要不良反应。27例患者出现世界卫生组织3 - 4级毒性，导致治疗延迟和剂量减少；4例患者停止治疗，8例患者无副作用。干扰素、达卡巴嗪和尼莫司汀联合治疗转移性黑色素瘤与干扰素和达卡巴嗪联合治疗相比无优势。
